The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Visseren, M. J.
Right arrow Articles by Melief, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Visseren, M. J.
Right arrow Articles by Melief, C. J.

The Journal of Immunology, Vol 154, Issue 8 3991-3998, Copyright © 1995 by American Association of Immunologists

ARTICLES

CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells

MJ Visseren, A van Elsas, EI van der Voort, ME Ressing, WM Kast, PI Schrier and CJ Melief
Department of Immunohematology, Leiden University Hospital, The Netherlands.

CTL that lyse melanoma cells were previously isolated from several melanoma patients. Such CTL recognize autologous proteins, indicating the occurrence of autoreactive T cells in melanoma patients. We have now raised CTL, using responding T lymphocytes from healthy donor blood, that lysed not only cells incubated with an HLA-A*0201-binding tyrosinase peptide but also melanoma cells endogenously processing and presenting the epitope. Our results suggest that autoreactive CTL precursors are present in healthy donor blood and can be activated in vitro with synthetic peptides presented on appropriate APCs. Therefore, tissue-specific, autoantigen-derived peptides might be useful in immunotherapy of both poorly and nonimmunogenic tumors.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Bendz, S. C. Ruhland, M. J. Pandya, O. Hainzl, S. Riegelsberger, C. Brauchle, M. P. Mayer, J. Buchner, R. D. Issels, and E. Noessner
Human Heat Shock Protein 70 Enhances Tumor Antigen Presentation through Complex Formation and Intracellular Antigen Delivery without Innate Immune Signaling
J. Biol. Chem., October 26, 2007; 282(43): 31688 - 31702.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
V. Milani, B. Frankenberger, O. Heinz, A. Brandl, S. Ruhland, R. D. Issels, and E. Noessner
Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response
Int. Immunol., March 1, 2005; 17(3): 257 - 268.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang and F. G. Haluska
Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways
J. Immunol., April 1, 2004; 172(7): 4599 - 4608.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. C. Kuppner, A. Scharner, V. Milani, C. von Hesler, K. E. Tschop, O. Heinz, and R. D. Issels
Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion
Blood, November 15, 2003; 102(10): 3668 - 3674.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Noessner, R. Gastpar, V. Milani, A. Brandl, P. J. S. Hutzler, M. C. Kuppner, M. Roos, E. Kremmer, A. Asea, S. K. Calderwood, et al.
Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells
J. Immunol., November 15, 2002; 169(10): 5424 - 5432.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Wolchok, P. B. Chapman, and M. S. Mitchell
Phase I Trial of Adoptive Immunotherapy With Cytolytic T Lymphocytes Immunized Against a Tyrosinase Epitope
J. Clin. Oncol., July 15, 2002; 20(14): 3176 - 3177.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
D Jager, E Jager, and A Knuth
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer
J. Clin. Pathol., September 1, 2001; 54(9): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P.-Y. Dietrich, P. R. Walker, A.-L. Quiquerez, G. Perrin, V. Dutoit, D. Liénard, P. Guillaume, J.-C. Cerottini, P. Romero, and D. Valmori
Melanoma Patients Respond to a Cytotoxic T Lymphocyte-defined Self-Peptide with Diverse and Nonoverlapping T-Cell Receptor Repertoires
Cancer Res., March 1, 2001; 61(5): 2047 - 2054.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
B. W. Anderson, G. E. Peoples, J. L. Murray, M. A. Gillogly, D. M. Gershenson, and C. G. Ioannides
Peptide Priming of Cytolytic Activity to HER-2 Epitope 369-377 in Healthy Individuals
Clin. Cancer Res., November 1, 2000; 6(11): 4192 - 4200.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Gervois, N. Labarriere, S. Le Guiner, M.-C. Pandolfino, J.-F. Fonteneau, Y. Guilloux, E. Diez, B. Dreno, and F. Jotereau
High Avidity Melanoma-reactive Cytotoxic T Lymphocytes Are Efficiently Induced from Peripheral Blood Lymphocytes on Stimulation by Peptide-pulsed Melanoma Cells
Clin. Cancer Res., April 1, 2000; 6(4): 1459 - 1467.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
S. Gomi, M. Nakao, F. Niiya, Y. Imamura, K. Kawano, S. Nishizaka, A. Hayashi, Y. Sobao, K. Oizumi, and K. Itoh
A Cyclophilin B Gene Encodes Antigenic Epitopes Recognized by HLA-A24-Restricted and Tumor-Specific CTLs
J. Immunol., November 1, 1999; 163(9): 4994 - 5004.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter
Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo
Cancer Res., October 1, 1999; 59(19): 4955 - 4963.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. de Ines, B. Cochlovius, S. Schmidt, S. Kipriyanov, H.-J. Rode, and M. Little
Apoptosis of a Human Melanoma Cell Line Specifically Induced by Membrane-Bound Single-Chain Antibodies
J. Immunol., October 1, 1999; 163(7): 3948 - 3956.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Valmori, M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J.-C. Cerottini, and P. Romero
Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376
Cancer Res., August 1, 1999; 59(16): 4050 - 4055.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Yang, M. Nakao, S. Shichijo, T. Sasatomi, H. Takasu, H. Matsumoto, K. Mori, A. Hayashi, H. Yamana, K. Shirouzu, et al.
Identification of a Gene Coding for a Protein Possessing Shared Tumor Epitopes Capable of Inducing HLA-A24-restricted Cytotoxic T Lymphocytes inCancer Patients
Cancer Res., August 1, 1999; 59(16): 4056 - 4063.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
S. Sarma, Y. Guo, Y. Guilloux, C. Lee, X.-F. Bai, and Y. Liu
Cytotoxic T Lymphocytes to An Unmutated Tumor Rejection Antigen P1A: Normal Development but Restrained Effector Function In Vivo
J. Exp. Med., March 1, 1999; 189(5): 811 - 820.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
I. V. Redchenko and A. B. Rickinson
Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells
J. Virol., January 1, 1999; 73(1): 334 - 342.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
G. S. Ogg, P. Rod Dunbar, P. Romero, J.-L. Chen, and V. Cerundolo
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo
J. Exp. Med., September 21, 1998; 188(6): 1203 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
D. E. Speiser, R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi
Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy
J. Exp. Med., August 29, 1997; 186(5): 645 - 653.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
M. P.M. Vierboom, H. W. Nijman, R. Offringa, E. I.H. v. d. Voort, T. v. Hall, L. v. d. Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J.M. Melief
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
J. Exp. Med., August 29, 1997; 186(5): 695 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Halaban, E. Cheng, Y. Zhang, G. Moellmann, D. Hanlon, M. Michalak, V. Setaluri, and D. N. Hebert
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells
PNAS, June 10, 1997; 94(12): 6210 - 6215.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
R.-F. Wang, E. Appella, Y. Kawakami, X. Kang, and S. A. Rosenberg
Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
J. Exp. Med., December 15, 1996; 184(6): 2207 - 2216.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.